Charles River Laboratories International (CRL) EBITDA (2009 - 2026)
Charles River Laboratories International (CRL) EBITDA from Jun 27, 2009 to Mar 28, 2026. The TTM Charles River Laboratories International (CRL) EBITDA is $420M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Charles River Laboratories International (CRL) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +4.49% |
| 3 Years TTM | -5.56% |
| 5 Years TTM | -2.58% |
| 10 Years TTM | +7.03% |
| All Time TTM | +10.25% |
Annual EBITDA change of Charles River Laboratories International (CRL)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $187M | -56.34% |
| 2025 | $428M | -27.27% |
| 2024 | $589M | -36.75% |
| 2023 | $931M | -2.46% |
| 2022 | $955M | +11.63% |
| 2021 | $855M | +28.12% |
| 2020 | $668M | +21.56% |
| 2019 | $549M | +11.37% |
| 2018 | $493M | +17.58% |
| 2017 | $419M | +15.16% |
| 2016 | $364M | +20.87% |
| 2015 | $301M | +9.93% |
| 2014 | $274M | +10.51% |
| 2013 | $248M | +0.40% |
| 2012 | $247M | -4.82% |
| 2011 | $260M | -226.69% |
| 2010 | -$205M | -178.92% |
| 2009 | $260M | -171.12% |
| 2008 | -$365M | N/A |
Comparison Charles River Laboratories International (CRL) five years EBITDA CAGR with competitors
Charles River Laboratories International (CRL) five years EBITDA CAGR is -9.73%.
| Ticker | Name | five years EBITDA CAGR | Upside |
|---|---|---|---|
| PRPH | ProPhase Labs Inc | 73.15% | -852.20% |
| MEDP | Medpace Holdings Inc | 25.16% | -358.71% |
| ISPC | iSpecimen Inc | 25.14% | -358.49% |
| PSNL | Personalis Inc | 18.83% | -293.59% |
| WAT | Waters Corp | 17.45% | -279.47% |
| BNR | Burning Rock Biotech Ltd | 17.26% | -277.49% |
| ICLR | Icon Plc | 12.53% | -228.87% |
| IDXX | Idexx Laboratories Inc | 11.66% | -219.93% |
| CSTL | Castle Biosciences Inc | 10.29% | -205.78% |
| MTD | Mettler-Toledo International Inc | 9.87% | -201.46% |
| MYNZ | Mainz Biomed N.V. | 9.82% | -200.98% |
| IQV | IQVIA Holdings Inc | 9.14% | -194.02% |
| RDNT | Radnet Inc | 8.38% | -186.22% |
| IMDX | Insight Molecular Diagnostics Inc | 7.62% | -178.31% |
| A | Agilent Technologies Inc | 6.59% | -167.75% |
| ILMN | Illumina Inc | 5.98% | -161.52% |
| GH | Guardant Health Inc | 5.67% | -158.31% |
| NTRA | Natera Inc | 3.35% | -134.46% |
| TWST | Twist Bioscience Corp | 2.84% | -129.19% |
| BDSX | Biodesix Inc | 2.43% | -125.03% |
| SHC | Sotera Health Company | 2.32% | -123.87% |
| QGEN | Qiagen NV | 2.21% | -122.68% |